Nasdaq · Healthcare
PUMA BIOTECHNOLOGY, INC. (PBYI)
As-reported financials and recent SEC filings for PUMA BIOTECHNOLOGY, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$228.4M
Net income
$31.1M
Net margin
13.6%
Diluted EPS
$0.61
ROE
23.9%
P/E (TTM)
16.9×
Market cap
$412.8M
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M |
| Gross profit | $170.2M | $166.1M | $173.0M | $172.9M | $189.5M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M |
| Net income | $31.1M | $30.3M | $21.6M | $2,000 | $-29.1M |
| Diluted EPS | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-16
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →Go deeper on PBYI
Search PUMA BIOTECHNOLOGY, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.